An International, Multicentre, Prospective, Single-Arm Study to Assess the Effect on Voluntary Movements of AbobotulinumtoxinA 1500 U Administered in Both Upper and Lower Limbs in Conjunction With a Guided Self-Rehabilitation Contract in Adult Subjects With Spastic Hemiparesis
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Paresis
- Focus Therapeutic Use
- Acronyms ENGAGE
- Sponsors Ipsen
- 07 Feb 2018 According to an Ipsen media release, this study will be presented at the World Congress for Neurorehabilitation (WCNR 2018).
- 27 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Oct 2017 According to an Ipsen media release, methodology of this study will be presented at at the annual assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) 2017.